Thrombospondin-1 Drives Cardiac Remodeling in Chronic Kidney Disease

Area of Science:

• Cardiovascular Science
• Nephrology
• Molecular Biology

Background:

• Patients with chronic kidney disease (CKD) exhibit a significantly elevated risk of cardiovascular disease.
• Endogenous thrombospondin 1 (TSP1) has been previously implicated in right ventricular remodeling and dysfunction.

Purpose of the Study:

• To investigate the role of TSP1 in the development of cardiac dysfunction in a murine model of CKD.
• To explore the in vitro mechanisms by which CKD-associated factors influence cardiac health via TSP1.
• To examine the expression of TSP1 and aryl hydrocarbon receptor in the myocardium of CKD patients.

Main Methods:

• Utilized a murine model of chronic kidney disease (CKD).
• Assessed myocardial TSP1 expression, left ventricular structure, and function.
• Employed in vitro studies using cardiomyocytes and indoxyl sulfate.
• Analyzed myocardial tissue from CKD patients for TSP1 and aryl hydrocarbon receptor expression.

Main Results:

• CKD mice exhibited increased myocardial TSP1 expression, leading to left ventricular hypertrophy, fibrosis, and dysfunction.
• TSP1 knockout mice were protected against CKD-induced cardiac abnormalities.
• In vitro, indoxyl sulfate induced detrimental cardiomyocyte changes mediated by TSP1.
• CKD patients showed differential expression of TSP1 and aryl hydrocarbon receptor in the myocardium.

Conclusions:

• TSP1 plays a critical role in mediating cardiac dysfunction and structural changes associated with CKD.
• Indoxyl sulfate contributes to these deleterious effects through TSP1.
• TSP1 represents a potential therapeutic target for cardiovascular complications in CKD patients.
• Further clinical studies are warranted to validate the translational significance of TSP1 in CKD.